AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Clinical trial NCT03959891 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03959891
- Sponsor
- Massachusetts General Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-30
- Primary completion
- 2022-12-25
- Enrollment
- 77
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.